Subsequently, the prospective comparison of ARNI with ARB global outcomes in HF with preserved ejection fraction (PARAGON‐HF)19 trial evaluated the efficacy of the addition of neprilysin inhibition (sacubitril) to valsartan versus only valsartan therapy in 4822 patients with HFpEF defined as an LVEF of >45%. Here, MME is linked to hydrops fetalis.